FMP
HilleVax, Inc.
HLVX
NASDAQ
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
1.86 USD
0.03 (1.61%)
We are unable to load this data!
We are unable to load the data!